Genomics

Dataset Information

0

Spectinomycin Analogs for the Treatment of Mycobacterium abscessus Infections


ABSTRACT: Non-tuberculous mycobacteria (NTM) are emerging pathogens with high intrinsic drug resistance. Among rapidly growing NTM species, Mycobacterium abscessus is among the most pathogenic. Standard of care therapy has led to unacceptable outcomes and demonstrates the urgent need to develop effective, broad-spectrum antimycobacterial regimens. Through synthetic modification of spectinomycin (SPC), an aminocyclitol antibiotic, we have identified a distinct structural subclass of ethylene linked aminomethyl spectinomycins (eAmSPC) that are up to 64-fold more potent against M. abscessus when compared to SPC. Lead eAmSPC retain activity against other NTM species and multi-drug resistant M. abscessus clinical isolates. Sequencing of eAmSPC-resistant mutants revealed nucleotide changes in the distinct helix-34 spectinomycin binding site and X-ray crystallography further demonstrated the derivatives mode of ribosomal inhibition remained on target. The eAmSPC displayed increased intracellular accumulation compared to SPC and transcriptional profiling indicate that eAmSPC’s induce whiB7 resistance responses, however, the series maintains potency despite its expression. These leads display favorable pharmacokinetic profiles and robust efficacy in M. abscessus mouse infection models. The results of these studies suggest that eAmSPCs have the potential to be developed into clinical treatments for M. abscessus and other NTM infections.

ORGANISM(S): Mycobacteroides abscessus ATCC 19977

PROVIDER: GSE222081 | GEO | 2023/01/09

REPOSITORIES: GEO

Similar Datasets

2024-03-01 | E-MTAB-13761 | biostudies-arrayexpress
2022-03-30 | GSE193092 | GEO
2023-11-14 | GSE233690 | GEO
2024-03-07 | PXD045930 | Pride
2024-03-07 | PXD040615 | Pride
2019-10-08 | PXD014255 | Pride
2022-08-10 | GSE207456 | GEO
2019-09-20 | GSE124972 | GEO
2023-11-30 | GSE239870 | GEO
2023-11-30 | GSE239869 | GEO